Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 15/20 | 1.00 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044256 | 0.96 | HCAR3 (1.00) | HCAR3SLC9A1PLA2G4AHPGDHCAR2 | |
| SCHEMBL6043651 | 0.95 | HCAR3 (0.97) | HCAR3SLC9A1PLA2G4AHPGDHCAR2 | |
| SCHEMBL6044508 | 0.92 | HCAR3 (1.00) | HCAR3SLC9A1PLA2G4AHPGDHCAR2 | |
| SCHEMBL6044288 | 0.87 | HCAR3 (0.78) | HCAR3PLA2G4AHPGDHCAR2 | |
| SCHEMBL15555892 | 0.86 | HCAR3 (0.76) | HCAR3HPGDHCAR2 | |
| SCHEMBL6044058 | 0.85 | HCAR3 (1.00) | HCAR3HPGDHCAR2 | |
| SCHEMBL6044277 | 0.85 | HCAR3 (0.74) | HCAR3PLA2G4AHPGDHCAR2 | |
| SCHEMBL6685414 | 0.85 | HCAR3 (0.85) | HCAR3PLA2G4AHPGDHCAR2 | |
| SCHEMBL6043994 | 0.83 | HCAR3 (0.71) | HCAR3PLA2G4AHPGDHCAR2 | |
| SCHEMBL29897702 | 0.83 | HCAR3 (0.71) | HCAR3PLA2G4AHPGDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | claimed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | claimed |
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| CN-1022184-C | Process for preparing (1 H-imidzol-1-ylmethyl) substituted benzotriazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1993-09-22 | — | — | CN | disclosed |
| EP-0293978-B1 | (1H-AZOL-1-YLMETHYL)SUBSTITUTED BENZOTRIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-09-15 | — | — | EP | disclosed |
| US-5039677-A | Estrogen inhibitor | JANSSEN PHARMACEUTICA N.V. (CA) | 1991-08-13 | — | — | US | disclosed |
| US-4943574-A | AROMATASE INHIBITORS, ESTROGEN DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-24 | — | — | US | disclosed |
| CN-88103408-A | Process for preparing (1H-oxazol-1-ylmethyl) substituted benzotriazole derivatives | — | 1988-12-14 | — | — | CN | disclosed |
| EP-0293978-A2 | (1H-azol-1-ylmethyl)substituted benzotriazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885SLC9A1 2649/4885PLA2G4A 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.